Sanofi, Bristol-Myers Fire Back In Plavix Feud
Hot on the heels of Apotex' launch of an at-risk generic version of Plavix earlier this month, Sanofi-Aventis and Bristol-Myers Squibb are lashing out at the generic drug maker, filing a...To view the full article, register now.
Already a subscriber? Click here to view full article